Modulación de la vía JAK/STAT/SOCS y sus implicaciones terapéuticas en cáncer y enfermedades inflamatorias
This article critically reviews the literature on JAK/STAT pathway biology, its roles in myeloproliferative, inflammatory, and neoplastic diseases, and advances in targeted pharmacological inhibition. The evidence reviewed indicates that cytokine-mediated JAK/STAT activation regulates essential cellular functions. Several inhibitors, including ruxolitinib, tofacitinib, and baricitinib, have demonstrated clinical efficacy in specific approved indications, such as myelofibrosis and rheumatoid arthritis. However, approved uses vary by drug and jurisdiction, while experimental compounds require further clinical validation. These findings underscore the pathway’s therapeutic relevance and the importance of distinguishing established clinical uses from preclinical evidence.
Authors
- Jonnathan Guadalupe Santillán Benítez (ORCID: https://orcid.org/0000-0003-3574-1231)
- Erasto Desales Salazar (ORCID: https://orcid.org/0009-0006-2702-4119)
- Mariam Jazive García López (ORCID: https://orcid.org/0009-0008-6876-0950)
Institutions
- Universidad Autónoma del Estado de México (MX)
Publication Details
- Journal
- Ibero Ciencias - Revista Científica y Académica
- Published
- 2026-11-13
- DOI
- https://doi.org/10.63371/ic.v5.n4.a1878
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00